---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-235469"
form_type: "8-K"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2026-05-22T11:15:16+00:00"
generated_at: "2026-05-22T11:20:50.645595+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Assembly Biosciences expands ABI-6250 into PBC and PSC; Phase 2 basket study planned Q1 2027

## Summary
- ABI-6250, oral NTCP inhibitor, to be studied in PBC and PSC basket Phase 2 starting Q1 2027.
- Phase 1a completed; data show dose-dependent bile acid elevations confirming target engagement.
- Chronic tox studies support longer-term dosing; Phase 2 in HDV remains on track for Q4 2026.
- Pre-IND FDA meeting constructive; company views feedback as helpful for advancement.
- PSC has no approved therapies; PBC has significant unmet need despite existing treatments.

## SEC filing metadata
- accession: 0001193125-26-235469
- form_type: 8-K
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2026-05-22T11:15:16+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000119312526235469/0001193125-26-235469-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000119312526235469/asmb-20260522.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-235469
- JSON: https://secwatch.observer/filing/0001193125-26-235469.json
- Plain text: https://secwatch.observer/filing/0001193125-26-235469.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.